New cancer Drug's interaction with common sedative tested

NCT ID NCT05509816

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study in 20 healthy women of non-childbearing potential looked at how repeat doses of imlunestrant, an experimental cancer drug, affect the body's ability to process midazolam, a common sedative. Participants took both drugs orally, and researchers measured drug levels in the blood over about 6 weeks. The goal was to understand potential drug interactions and ensure safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imlunestrant
What this could lead to: If successful, this study could help doctors understand how imlunestrant interacts with other drugs, leading to safer dosing guidelines.
What could go wrong: This is an early, small study in healthy volunteers, not patients. It only measures drug levels, not treatment effects, so results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

LabCorp CRU, Inc.

Daytona Beach, Florida, 32117, United States
LabCorp CRU, Inc.

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.